1
|
Nishigaichi A, Amano Y, Sada RM, Miyake H, Maruyama W, Tagawa S, Akebo H, Hatta K, Nishino I. A Case of Amyloid Myopathy Mimicking Anti-Mi-2 Antibody-Positive Myositis. J Gen Intern Med 2024:10.1007/s11606-024-09012-1. [PMID: 39249649 DOI: 10.1007/s11606-024-09012-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2024] [Accepted: 08/16/2024] [Indexed: 09/10/2024]
Affiliation(s)
- Akira Nishigaichi
- Department of General Internal Medicine, Tenri Hospital, Nara, Japan
- Department of Rheumatology and Allergology, NHO Osaka Minami Medical Center, Kawachinagano, Japan
| | - Yu Amano
- Department of General Internal Medicine, Tenri Hospital, Nara, Japan
- Department of Cardiology, Tenri Hospital, Nara, Japan
| | - Ryuichi Minoda Sada
- Department of General Internal Medicine, Tenri Hospital, Nara, Japan.
- Department of Transformative Protection to Infectious Disease, Graduate School of Medicine, Osaka University, Osaka, Japan.
- Department of Infection Control, Graduate School of Medicine, Osaka University, Osaka, Japan.
| | - Hirofumi Miyake
- Department of General Internal Medicine, Tenri Hospital, Nara, Japan
| | | | - Shunsuke Tagawa
- Department of General Internal Medicine, Tenri Hospital, Nara, Japan
| | - Hiroyuki Akebo
- Department of General Internal Medicine, Tenri Hospital, Nara, Japan
| | - Kazuhiro Hatta
- Department of General Internal Medicine, Tenri Hospital, Nara, Japan
| | - Ichizo Nishino
- Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan
- Department of Clinical Development, Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan
| |
Collapse
|
2
|
Koizumi H, Muro Y, Yamashita Y, Takeichi T, Fritzler MJ, Akiyama M. Anti-KIF20B autoantibodies in systemic autoimmune rheumatic diseases: Their high prevalence in systemic lupus erythematosus. J Dermatol 2023; 50:990-998. [PMID: 37102216 DOI: 10.1111/1346-8138.16813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Revised: 03/06/2023] [Accepted: 04/12/2023] [Indexed: 04/28/2023]
Abstract
The kinesin superfamily protein 20B (KIF20B), also known as M-phase phosphoprotein-1, is a plus-end-directed motor enzyme for cytokinesis. Anti-KIF20B antibodies have been reported in idiopathic ataxia, but no previous studies have examined anti-KIF20B antibodies in systemic autoimmune rheumatic diseases (SARDs). We aimed to establish methods for detecting anti-KIF20B antibodies and to investigate the clinical significance of these antibodies in SARDs. Serum samples from 597 patients with various SARDs and 46 healthy controls (HCs) were included. Fifty-nine samples that had been examined by immunoprecipitation using the recombinant KIF20B protein produced by in vitro transcription/translation were used for establishing the ELISA cutoff with the same recombinant protein for measuring the anti-KIF20B antibodies. The ELISA performed well, showing close agreement with the immunoprecipitation results (Cohen's κ >0.8). The ELISA results for 643 samples showed the prevalence of anti-KIF20B to be higher in the systemic lupus erythematosus (SLE) patients than in the HCs (18/89 vs. 3/46, P = 0.045). Since no SARD other than SLE had higher frequencies of anti-KIF20B antibodies than those of the HCs, we investigated the clinical characteristics of anti-KIF20B antibody-positive cases in SLE. The score on the SLE Disease Activity Index-2000 (SLEDAI-2K) was significantly higher for the anti-KIF20B-positive SLE patients than for the anti-KIF20B-negative SLE patients (P = 0.013). In a multivariate regression analysis of the anti-single-stranded deoxyribonucleic acid, anti-double-stranded deoxyribonucleic acid, and anti-KIF20B antibodies, the presence of anti-KIF20B antibody was significantly associated with high SLEDAI-2K scores (P = 0.003). Anti-KIF20B antibodies were found in ~20% of patients with SLE and were associated with high SLEDAI-2K scores. Much larger cohort and longitudinal studies are needed to confirm the association between anti-KIF20B antibodies and SLE.
Collapse
Affiliation(s)
- Haruka Koizumi
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yoshinao Muro
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yuta Yamashita
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Takuya Takeichi
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Marvin J Fritzler
- Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada
| | - Masashi Akiyama
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
3
|
Loganathan A, McMorrow F, Lu H, Li D, Mulhearn B, McHugh NJ, Tansley SL. The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population. Front Immunol 2022; 13:975939. [PMID: 36177007 PMCID: PMC9514093 DOI: 10.3389/fimmu.2022.975939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 08/08/2022] [Indexed: 11/13/2022] Open
Abstract
BackgroundThe reliable detection of myositis-specific autoantibodies (MSA) provides valuable clinical information regarding prognosis, clinical progression and diagnostic confirmation.ObjectivesTo evaluate the reliability of a commercial ELISA immunoassay in detecting myositis-specific autoantibodies in comparison to immunoprecipitation as the reference standard.MethodsSerum samples were chosen from a biobank of more than 3000 samples. Samples with a confirmed MSA on Immunoprecipitation (n=116) were evaluated in duplicate by ELISA to detect Mi2, MDA5, Jo1, EJ, KS, PL-7 and PL-12 (Medical & Biological Laboratories Co. Ltd, Nagoya, Aichi, Japan). Healthy control samples (n=246) confirmed autoantibody negative by immunoprecipitation were similarly assessed.ResultsThere was a very good agreement between ELISA and immunoprecipitation for serum samples containing anti-Mi2, MDA5, Jo1, EJ, KS and PL-7 and PL-12 auto-antibodies. Cohen’s κ values ranged from 0.86-1 for the measured autoantibodies on ELISA.ConclusionELISA was an accurate method for detecting anti-synthetase, anti-Mi2 and anti-MDA5 autoantibodies.
Collapse
Affiliation(s)
- Aravinthan Loganathan
- Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
- Department and Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
- *Correspondence: Aravinthan Loganathan,
| | - Fionnuala McMorrow
- Department and Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
| | - Hui Lu
- Department and Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
| | - Danyang Li
- Department and Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
| | - Ben Mulhearn
- Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
- Department and Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
| | - Neil John McHugh
- Department and Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
| | - Sarah Louise Tansley
- Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
- Department and Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
| |
Collapse
|
4
|
Yamashita Y, Yamano Y, Muro Y, Ogawa-Momohara M, Takeichi T, Kondoh Y, Akiyama M. Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia. Rheumatology (Oxford) 2021; 61:1709-1716. [PMID: 34282441 DOI: 10.1093/rheumatology/keab575] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 07/09/2021] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE Anti-NOR90 antibodies are usually found in patients with systemic sclerosis (SSc); however, their clinical relevance remains obscure. We developed an enzyme-linked immunosorbent assay (ELISA) for measuring them to investigate the clinical features of patients with anti-NOR90 antibodies. METHODS Serum samples from 1,252 patients with various conditions from Nagoya University Hospital and 244 patients with idiopathic interstitial pneumonia (IIP) from Tosei General Hospital were included. Anti-NOR90 antibodies were assayed by an ELISA using the recombinant protein produced by in vitro transcription/translation. RESULTS Five (0.4%) patients in the Nagoya University Hospital cohort had anti-NOR90 antibodies. One patient with diffuse cutaneous SSc, 3 with limited cutaneous SSc, and 1 with Raynaud's disease were positive for anti-NOR90 antibodies. Anti-NOR90 antibodies were found more frequently in patients with systemic scleroderma-spectrum disorders (SSDs) than without SSDs (5/316 vs. 0/936, P<0.00101) and were found more frequently in patients with SSc than without SSc (4/249 vs. 0/528, P<0.0104) in the systemic autoimmune rheumatic diseases cohort. Three of the 4 anti-NOR90-positive SSc patients had interstitial lung disease (ILD), and 2 of those 4 had cancer. Three (1.2%) patients in the Tosei General Hospital cohort had anti-NOR90 antibodies. All 3 of the anti-NOR90-positive IIP patients had gastrointestinal tract involvement, and 2 of those 3 had cancer or skin lesions observed in SSc. CONCLUSIONS Although anti-NOR90 antibodies are rarely found in clinics, our ELISA is useful for their detection. Further studies are needed to confirm the association of anti-NOR90 antibodies with ILD and cancer in SSc and IIP patients.
Collapse
Affiliation(s)
- Yuta Yamashita
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Yasuhiko Yamano
- Department of Respiratory and Allergic Medicine, Tosei General Hospital, Seto, Aichi 489-8642, Japan
| | - Yoshinao Muro
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Mariko Ogawa-Momohara
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Takuya Takeichi
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Yasuhiro Kondoh
- Department of Respiratory and Allergic Medicine, Tosei General Hospital, Seto, Aichi 489-8642, Japan
| | - Masashi Akiyama
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| |
Collapse
|
5
|
Ogawa-Momohara M, Kinoshita F, Muro Y, Kobayashi Y, Takeichi T, Akiyama M. Autoantibody profiles in patients' sera associated with distribution patterns of dermatomyositis skin symptoms. J Am Acad Dermatol 2021; 84:1720-1722. [PMID: 33867178 DOI: 10.1016/j.jaad.2020.07.131] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 07/14/2020] [Accepted: 07/20/2020] [Indexed: 11/29/2022]
Affiliation(s)
- Mariko Ogawa-Momohara
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Fumie Kinoshita
- Division of Data Science, Data Coordinating Center, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan
| | - Yoshinao Muro
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
| | - Yumiko Kobayashi
- Division of Data Science, Data Coordinating Center, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan
| | - Takuya Takeichi
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Masashi Akiyama
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
6
|
Hodgkinson LM, Wu TT, Fiorentino DF. Dermatomyositis autoantibodies: how can we maximize utility? ANNALS OF TRANSLATIONAL MEDICINE 2021; 9:433. [PMID: 33842654 PMCID: PMC8033377 DOI: 10.21037/atm-20-5175] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The past 15 years has seen significant advances in the characterization of myositis-specific autoantibodies (MSAs) and their associated phenotypes in patients with dermatomyositis (DM). As more careful studies are performed, it is clear that unique combinations of clinical and pathological phenotypes are associated with each MSA, despite the fact that there is considerable heterogeneity within antibody classes as well as overlap across the groups. Because risk for interstitial lung disease (ILD), internal malignancy, adverse disease trajectory, and, potentially response to therapy differ by DM MSA group, a deeper understanding of MSAs and validation and standardization of assays used for detection are critical for optimizing diagnosis and treatment. Like any test, the diagnostic sensitivity and specificity of assays for various MSAs is not perfect. Currently tests for MSAs are helpful at minimum for a clinician to assess relative risk or contribute to diagnosis and perhaps counsel the appropriate patient about what to expect. With international standardization and larger studies it is likely that more antibody tests will make their way into formal schemata for diagnosis and actionable risk assessment in DM. In this review, we summarize key considerations for interpreting the clinical and pathologic associations with MSA in DM and identify critical gaps in knowledge and practice that will maximize their clinical utility and utility for understanding disease pathogenesis.
Collapse
Affiliation(s)
| | - Tiffany Tingshuen Wu
- Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA
| | | |
Collapse
|
7
|
Yoshikawa M, Muro Y, Ogawa-Momohara M, Ito S, Takeichi T, Akiyama M. A case with overlapping features of IgG4-related autoimmune pancreatitis, Sjögren's syndrome and anti-aminoacyl-tRNA synthetase syndrome. Mod Rheumatol Case Rep 2020; 5:82-86. [PMID: 32867620 DOI: 10.1080/24725625.2020.1816675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
A 55-year-old man who had been diagnosed with autoimmune pancreatitis five years earlier was referred to our department because of finger swelling, finger stiffness and the presence of interstitial lung disease (ILD). The patient was diagnosed with Sjögren's syndrome according to the pathological findings of minor salivary glands and positive anti-SS-A antibodies. Later, at age 58, he was hospitalised due to the exacerbation of the ILD. Serum IgG4 level was checked and was found to be elevated (417 mg/dL). After the introduction of cyclosporine in addition to the prednisolone, at age 60, the ILD disease activity stabilised. However, at age 62, fever, myalgia and mechanic's hands appeared. His serum creatine kinase level was high, and magnetic resonance imaging showed inflammatory findings of muscle. In-house ELISA clarified that his serum carried anti-PL-7 antibody among anti-aminoacyl-tRNA synthetase antibodies. This is a unique case who had overlapping features of IgG4-related autoimmune pancreatitis, Sjögren's syndrome and anti-synthetase syndrome. Although the aetiology of the complications in this patient is obscure, autoimmunity might have played a significant role in the disease conditions and prognosis of the present case with IgG4-related disease.
Collapse
Affiliation(s)
- Masato Yoshikawa
- Division of Dermatology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan
| | - Yoshinao Muro
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Mariko Ogawa-Momohara
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Satoru Ito
- Department of Respiratory Medicine and Allergology, Aichi Medical University, Nagakute, Japan
| | - Takuya Takeichi
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Masashi Akiyama
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
8
|
Ogawa-Momohara M, Muro Y, Mitsuma T, Katayama M, Yanaba K, Nara M, Kakeda M, Akiyama M. Clinical characteristics of anti-Ro52α and anti-Ro52β antibodies in dermatomyositis/polymyositis. J Dermatol Sci 2019; 96:50-52. [PMID: 31444014 DOI: 10.1016/j.jdermsci.2019.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 07/25/2019] [Accepted: 08/06/2019] [Indexed: 10/26/2022]
Affiliation(s)
- Mariko Ogawa-Momohara
- Department of Dermatology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan
| | - Yoshinao Muro
- Department of Dermatology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
| | - Teruyuki Mitsuma
- Department of Dermatology, Ichinomiya Municipal Hospital, Ichinomiya, Japan
| | - Masao Katayama
- Department of Internal Medicine, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan
| | - Koichi Yanaba
- Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan
| | - Mizuho Nara
- Department of Hematology, Nephrology and Rheumatology, Akita University Hospital, Akita, Japan
| | - Masato Kakeda
- Department of Dermatology, Mie University, Graduate School of Medicine, Tsu, Japan
| | - Masashi Akiyama
- Department of Dermatology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan
| |
Collapse
|
9
|
Ogawa‐Momohara M, Muro Y, Akiyama M. Anti‐Mi‐2 antibody titers and cutaneous manifestations in dermatomyositis. JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY 2019. [DOI: 10.1002/cia2.12048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Affiliation(s)
| | - Yoshinao Muro
- Department of DermatologyNagoya University Graduate School of Medicine Nagoya Japan
| | - Masashi Akiyama
- Department of DermatologyNagoya University Graduate School of Medicine Nagoya Japan
| |
Collapse
|
10
|
Iwata N, Nakaseko H, Kohagura T, Yasuoka R, Abe N, Kawabe S, Sugiura S, Muro Y. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan. Mod Rheumatol 2018; 29:802-807. [DOI: 10.1080/14397595.2018.1511025] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Naomi Iwata
- Department of Infection and Immunology, Aichi Children’s Health and Medical Center, Obu, Japan
| | - Haruna Nakaseko
- Department of Infection and Immunology, Aichi Children’s Health and Medical Center, Obu, Japan
| | - Toaki Kohagura
- Department of Infection and Immunology, Aichi Children’s Health and Medical Center, Obu, Japan
| | - Ryuhei Yasuoka
- Department of Infection and Immunology, Aichi Children’s Health and Medical Center, Obu, Japan
| | - Naoki Abe
- Department of Infection and Immunology, Aichi Children’s Health and Medical Center, Obu, Japan
| | - Shinji Kawabe
- Department of Infection and Immunology, Aichi Children’s Health and Medical Center, Obu, Japan
| | - Shiro Sugiura
- Department of Allergy, Aichi Children’s Health and Medical Center, Obu, Japan
| | - Yoshinao Muro
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
11
|
Ahmed A, Scarborough R, Gabriela R, Fernandez AP, Bergfeld W. Seronegative dermatomyositis presenting with features of anti-MDA5 subtype. J Cutan Pathol 2018; 45:851-854. [DOI: 10.1111/cup.13324] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 07/12/2018] [Accepted: 07/13/2018] [Indexed: 01/09/2023]
Affiliation(s)
- Aadil Ahmed
- Department of Pathology; Loyola University Medical Center; Maywood Illinois
| | | | - Rosa Gabriela
- Department of Pathology; Cleveland Clinic; Cleveland Ohio
| | - Anthony P. Fernandez
- Department of Pathology; Cleveland Clinic; Cleveland Ohio
- Department of Dermatology; Cleveland Clinic; Cleveland Ohio
| | - Wilma Bergfeld
- Department of Pathology; Cleveland Clinic; Cleveland Ohio
- Department of Dermatology; Cleveland Clinic; Cleveland Ohio
| |
Collapse
|
12
|
Teraishi M, Nakajima K, Ishimoto T, Yamamoto M, Maeda N, Muro Y, Sano S. Anti-transcription intermediary factor 1γ antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer. Int J Rheum Dis 2018; 21:900-902. [PMID: 29341447 DOI: 10.1111/1756-185x.13264] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Mika Teraishi
- Department of Dermatology and, Kochi Medical School, Kochi University, Kochi, Japan
| | - Kimiko Nakajima
- Department of Dermatology and, Kochi Medical School, Kochi University, Kochi, Japan
| | - Tatsushi Ishimoto
- Department of Dermatology and, Kochi Medical School, Kochi University, Kochi, Japan
| | - Mayuko Yamamoto
- Department of Dermatology and, Kochi Medical School, Kochi University, Kochi, Japan
| | - Nagamasa Maeda
- Department of Obstetrics and Gynecology, Kochi Medical School, Kochi University, Kochi, Japan
| | - Yoshinao Muro
- Departments of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Shigetoshi Sano
- Department of Dermatology and, Kochi Medical School, Kochi University, Kochi, Japan
| |
Collapse
|
13
|
Yoshida K, Ito H, Ukichi T, Matsushita T, Furuya K, Noda K, Muro Y, Kurosaka D. Fasciitis as a disease manifestation in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies: a case report of two cases. Rheumatol Adv Pract 2018; 2:rky015. [PMID: 31431963 PMCID: PMC6649898 DOI: 10.1093/rap/rky015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Revised: 04/19/2018] [Accepted: 04/24/2018] [Indexed: 11/15/2022] Open
Affiliation(s)
- Ken Yoshida
- Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
| | - Haruyasu Ito
- Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
| | - Taro Ukichi
- Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
| | - Takayuki Matsushita
- Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
| | - Kazuhiro Furuya
- Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
| | - Kentro Noda
- Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
| | - Yoshinao Muro
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Daitaro Kurosaka
- Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
| |
Collapse
|
14
|
Autoantibodies to Su/Argonaute 2 in Japanese patients with inflammatory myopathy. Clin Chim Acta 2017; 471:304-307. [PMID: 28673815 DOI: 10.1016/j.cca.2017.06.022] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Revised: 06/29/2017] [Accepted: 06/29/2017] [Indexed: 01/05/2023]
Abstract
BACKGROUND Anti-Su antibodies are found in 5-20% of cases of various systemic autoimmune rheumatic diseases and in 5-10% of dermatomyositis (DM)/polymyositis (PM) patients. In 2006, the 100kDa Su antigen was identified as argonaute2 (Ago2), and it was found to play a major role in RNA interference. However, immunoprecipitation (IP) remains the main method for detecting anti-Su and the clinical significance of the antibodies is uncertain. METHODS Sera from patients with DM/PM (n=224) were screened by an ELISA that uses recombinant biotinylated Ago2 protein. Some serum samples were tested by IP and by indirect immunofluorescence (IIF) analysis. RESULTS Seventeen (7.5%, 17/224) sera from DM/PM were positive in ELISA. Of the 33 IP-tested sera (17 ELISA-positive and 16 ELISA-negative with high background), 13 were found to be anti-Ago2/Su-positive in IP and ELISA. Only one IP-positive serum was judged to be ELISA-negative. Among the 13 patients with anti-Su/Ago2, 7 cases also had myositis-specific autoantibodies. Six sera that were positive by both IP and ELISA showed the GW body pattern in IIF. Interestingly, one ELISA-positive serum with an inconclusive result in IP also showed the GW body pattern. CONCLUSION Our novel ELISA appears to be useful for screening anti-Su/Ago2 antibodies (sensitivity: 93%, specificity: 79%).
Collapse
|
15
|
MURO YOSHINAO, IWATA NAOMI, TANAKA YOSHIHITO, KODERA MASANARI, KONO MICHIHIRO, AKIYAMA MASASHI. Anti-dense Fine Speckled 70 Autoantibodies in Japanese Children with Dermatomyositis, Localized Scleroderma, and Idiopathic Arthritis with Iridocyclitis. J Rheumatol 2017; 44:711-712. [DOI: 10.3899/jrheum.161409] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
16
|
Kohara A, Yanaba K, Muro Y, Ito H, Nakagawa H, Noda K, Kurosaka D. Anti-PM/Scl antibody-positive dermatomyositis in a Japanese patient: a case report and review of the literature. Int J Rheum Dis 2017; 20:2186-2189. [DOI: 10.1111/1756-185x.13019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Aki Kohara
- Department of Dermatology; The Jikei University School of Medicine; Tokyo Japan
| | - Koichi Yanaba
- Department of Dermatology; The Jikei University School of Medicine; Tokyo Japan
| | - Yoshinao Muro
- Department of Dermatology; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - Hideki Ito
- Department of Dermatology; The Jikei University School of Medicine; Tokyo Japan
| | - Hidemi Nakagawa
- Department of Dermatology; The Jikei University School of Medicine; Tokyo Japan
| | - Kentaro Noda
- Department of Rheumatology; The Jikei University School of Medicine; Tokyo Japan
| | - Daitaro Kurosaka
- Department of Rheumatology; The Jikei University School of Medicine; Tokyo Japan
| |
Collapse
|
17
|
Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clin Rev Allergy Immunol 2017; 52:1-19. [PMID: 26424665 DOI: 10.1007/s12016-015-8510-y] [Citation(s) in RCA: 253] [Impact Index Per Article: 36.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Autoantibodies specific for idiopathic inflammatory myopathy (myositis-specific autoantibodies (MSAs)) are clinically useful biomarkers to help the diagnosis of polymyositis/dermatomyositis (PM/DM). Many of these are also associated with a unique clinical subset of PM/DM, making them useful in predicting and monitoring certain clinical manifestations. Classic MSAs known for over 30 years include antibodies to Jo-1 (histidyl transfer RNA (tRNA) synthetase) and other aminoacyl tRNA synthetases (ARS), anti-Mi-2, and anti-signal recognition particle (SRP). Anti-Jo-1 is the first autoantibodies to ARS detected in 15-25 % of patients. In addition to anti-Jo-1, antibodies to seven other aminoacyl tRNA synthetases (ARS) have been reported with prevalence, usually 1-5 % or lower. Patients with any anti-ARS antibodies are associated with anti-synthetase syndrome characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud's phenomenon, and others. Several recent studies suggested heterogeneity in clinical features among different anti-ARS antibody-positive patients and anti-ARS may also be found in idiopathic ILD without myositis. Anti-Mi-2 is a classic marker for DM and associated with good response to steroid treatment and good prognosis. Anti-SRP is specific for PM and associated with treatment-resistant myopathy histologically characterized as necrotizing myopathy. In addition to classic MSAs, several new autoantibodies with strong clinical significance have been described in DM. Antibodies to transcription intermediary factor 1γ/α (TIF1γ/α, p155/140) are frequently found in DM associated with malignancy while anti-melanoma differentiation-associated gene 5 (MDA5; CADM140) are associated with clinically amyopathic DM (CADM) complicated by rapidly progressive ILD. Also, anti-MJ/nuclear matrix protein 2 (NXP-2) and anti-small ubiquitin-like modifier-1 (SUMO-1) activating enzyme (SAE) are recognized as new DM-specific autoantibodies. Addition of these new antibodies to clinical practice in the future will help in making earlier and more accurate diagnoses and better management for patients.
Collapse
Affiliation(s)
- Minoru Satoh
- Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Japan, 1-1 Isei-ga-oka, Yahata-nishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan.
| | - Shin Tanaka
- Department of Human Information and Sciences, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Angela Ceribelli
- Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Via A. Manzoni 56, 20089, Rozzano (Milan), Italy.,BIOMETRA Department, University of Milan, Via Vanvitelli 32, 20129, Milan, Italy
| | - S John Calise
- Department of Oral Biology, University of Florida, Gainesville, FL, USA
| | - Edward K L Chan
- Department of Oral Biology, University of Florida, Gainesville, FL, USA
| |
Collapse
|
18
|
Waseda Y, Johkoh T, Egashira R, Sumikawa H, Saeki K, Watanabe S, Matsunuma R, Takato H, Ichikawa Y, Hamaguchi Y, Shiraki A, Muro Y, Yasui M, Prosch H, Herold C, Kasahara K. Antisynthetase syndrome: Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases. Eur J Radiol 2016; 85:1421-6. [DOI: 10.1016/j.ejrad.2016.05.012] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Revised: 05/07/2016] [Accepted: 05/23/2016] [Indexed: 01/11/2023]
|
19
|
Tsujikawa K, Hara K, Muro Y, Nakanishi H, Niwa Y, Koike M, Noda S, Riku Y, Sahashi K, Atsuta N, Ito M, Shimoyama Y, Akiyama M, Katsuno M. HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma. Neurology 2016; 87:841-3. [PMID: 27449065 DOI: 10.1212/wnl.0000000000003006] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2015] [Accepted: 05/09/2016] [Indexed: 11/15/2022] Open
Affiliation(s)
- Koyo Tsujikawa
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Kazuhiro Hara
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Yoshinao Muro
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Hirotaka Nakanishi
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Yukiko Niwa
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Masahiko Koike
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Seiya Noda
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Yuichi Riku
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Kentaro Sahashi
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Naoki Atsuta
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Mizuki Ito
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Yoshie Shimoyama
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Masashi Akiyama
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan
| | - Masahisa Katsuno
- From the Department of Neurology (K.T., K.H., H.N., S.N., Y.R., K.S., N.A., M.I., M. Katsuno), Department of Dermatology (Y.M., M.A.), Department of Gastroenterological Surgery (Surgery II) (Y.N., M. Koike), and Department of Pathology and Laboratory Medicine/Diagnostic Pathology (Y.S.), Nagoya University Graduate School of Medicine, Japan.
| |
Collapse
|
20
|
Cavazzana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabellese N, Tincani A, Satoh M, Franceschini F. Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods 2016; 433:1-5. [DOI: 10.1016/j.jim.2016.02.017] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 01/29/2016] [Accepted: 02/17/2016] [Indexed: 10/22/2022]
|
21
|
|
22
|
Muro Y, Sugiura K, Nara M, Sakamoto I, Suzuki N, Akiyama M. High incidence of cancer in anti-small ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis: Table 1. Rheumatology (Oxford) 2015; 54:1745-7. [DOI: 10.1093/rheumatology/kev247] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
23
|
Muro Y, Hosono Y, Sugiura K, Ogawa Y, Mimori T, Akiyama M. Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ther 2015; 17:57. [PMID: 25885224 PMCID: PMC4407870 DOI: 10.1186/s13075-015-0573-x] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2014] [Accepted: 02/20/2015] [Indexed: 01/09/2023] Open
Abstract
Introduction Anti-PM/Scl antibodies are associated with polymyositis (PM)/systemic scleroderma (SSc) overlap syndromes and are also found in other systemic autoimmune diseases. Although anti-PM/Scl reactivity is found in 3-11% of PM or SSc patients and in approximately 25% of PM/SSc overlap patients, previous large studies of Japanese patients with scleroderma reported that anti-PM/Scl are not found in Japanese patients at all. The PM/Scl autoantigen complex comprises 11–16 different polypeptides; ELISA with PM1-α peptide, which is a major epitope of the PM/Scl complex, has frequently been used for the detection of these antibodies in recent studies. However, no ELISA kit is commercially available in Japan. Methods In this study, we developed an immunoassay for measuring antibodies against recombinant PM/Scl-100 and PM/Scl-75 polypeptides, which are the two major targets of the complex, and we investigated their presence in 600 Japanese patients with various systemic autoimmune conditions. Immunoprecipitation analysis using the recombinants in addition to traditional radiolabeled cell extracts were also applied to ELISA-positive sera. Results In ELISA, 11 patients were positive for anti-PM/Scl-100 antibodies and 7 of these 11 patients were also positive for anti-PM/Scl-75 antibodies. Immunoprecipitation analysis using the recombinants in addition to traditional radiolabeled cell extracts confirmed that 9 out of these 11 patients immunoprecipitated the typical sets of PM/Scl proteins. In total, 4/16 (25%) undifferentiated connective tissue disease (UCTD) patients, 3/126 (2.4%) dermatomyositis patients, 1/223 (0.4%) SSc patients, 1/88 (1.1%) Sjögren’s syndrome patients, 0/123 patients with systemic lupus erythematosus, 0/17 patients with overlap syndrome and 0/7 patients with PM were judged to be positive for anti-PM/Scl antibodies. Conclusions This is the first report of Japanese autoimmune patients with anti-PM/Scl antibodies. In Japanese patients, anti-PM/Scl antibodies are only very rarely found, and they are not always specific for dermatomyositis (DM) or SSc; they are also present in various autoimmune conditions with the highest prevalence being in UCTD. All anti-PM/Scl-positive DM cases are complicated with interstitial lung disease and/or cancer, while no life-threatening involvement was found in other anti-PM/Scl-positive cases. Further studies on larger cohorts are necessary to define the clinical significance of anti-PM/Scl antibodies in autoimmune diseases.
Collapse
Affiliation(s)
- Yoshinao Muro
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. .,Division of Connective Tissue Disease and Autoimmunity, Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
| | - Yuji Hosono
- Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, 606-8507, Japan.
| | - Kazumitsu Sugiura
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
| | - Yasushi Ogawa
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
| | - Tsuneyo Mimori
- Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, 606-8507, Japan.
| | - Masashi Akiyama
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
| |
Collapse
|
24
|
Brief Report: Autoantibodies to DNA Mismatch Repair Enzymes in Polymyositis/Dermatomyositis and Other Autoimmune Diseases: A Possible Marker of Favorable Prognosis. Arthritis Rheumatol 2014; 66:3457-62. [DOI: 10.1002/art.38866] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2014] [Revised: 07/24/2014] [Accepted: 08/26/2014] [Indexed: 12/11/2022]
|
25
|
Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci 2014; 74:187-92. [DOI: 10.1016/j.jdermsci.2014.02.006] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2014] [Accepted: 02/24/2014] [Indexed: 10/25/2022]
|